Goodwin and KPMG hosted their 5th Annual Symposium on January 10, 2024, during the 42nd Annual JP Morgan Healthcare Conference.
Experts and practitioners delved into strategies that are enabling life sciences companies to enhance research and development; optimize value from licensing, M&A, and other transactions; and secure capital for growth.
2024 Agenda & Videos
- Kristin Ciriello Pothier — Global and US Leader, HCLS Deal Advisory and Strategy, KPMG
- Yusuf Henriques — CEO of IndyGeneUs AI
- Bonnie Anderson — CEO of PinkDx
- Karen Madden — Chief Technology Officer, MilliporeSigma
- Maital Rasmussen — Chief Commercial Officer, Octave Bio
- Jeff Stoll — Principal, KPMG, National Strategy Lead, Life Sciences
- Matt Wetzel — Partner, Goodwin, Life Sciences
- Sophie McGrath — Partner, Goodwin, Life Sciences
- Adam Fliss — Founding Partner, General Counsel, Patients Square Capital
- Ari Brettman M.D. — Senior Managing Director, Blackstone, Life Sciences
- Claudine Prowse, Ph.D. — Venture Partner, J.P. Morgan, Life Sciences Private Capital, J.P. Morgan Asset Management
- Chris Wilson (moderator) — Partner, Goodwin Health
- Jarrod Smith — Principal, Varsity Healthcare Partners
- Lee Mooney — Managing Director, Sixth Street Growth
- Ross Nelson, MD —National Healthcare Strategy Leader, KPMG
Due to privacy concerns, this recording is not available.
- John Jones — Partner, Goodwin, Health
- Matt Wetzel — Partner, Goodwin, Life Sciences
- Johnathan Ishee — Partner, Goodwin, Health
- Joe Harrington — Partner, Goodwin, Health
- Gregory Demske — Partner, Goodwin, Health
- Jaime Pego — Principal, KPMG
- Sergiu P. Pasca, M.D. — Kenneth T. Norris, Jr. Professor of Psychiatry and Behavioral Sciences; Bonnie Uytengsu and Family Director of Stanford Brain Organogenesis, Stanford University
- Danielle Lauzon — Partner, Goodwin, Life Sciences
- Jennifer Plotnick — Audit Partner, US Venture Capital Life Sciences Co-Leader
- Brian Goodman — Partner, MPM BioImpact
- Melissa Danforth — General Counsel, Bain Capital
- Karan Takhar — Managing Director, Matrix Capital Management
- Rahul Rao — Deputy Director of the FTC’s Bureau of Competition
- Arman Oruc — Partner, Goodwin
- Sarah Solomon — Partner, Goodwin, Life Sciences
- Chris Rigoli — Executive Director, Morgan Stanley
Due to privacy concerns, this recording is not available.
- Rachael Bushey — Partner, Goodwin, Life Sciences
- David Happel — CEO and Director, Sagimet Biosciences
- Brian McVeigh — Chairman, CEO & Co-Founder, Code Biotherapeutics
- Jason Trimborn — Audit Partner, US Venture Capital Life Sciences Co-Leader
- Srini Akkaraju — Founder and Managing General Partner, Samsara
- Heather Turner — CEO, Carnot Therapeutics
- Marianne Sarrazin — Partner, Goodwin, Life Sciences
- Shari Mager — Deal Advisory Partner, KPMG, US National Capital Markets Readiness Leader
- Sam Backenroth — CFO & Strategic Leadership, LS Associates; Co-Founder at Orphion Therapeutics
- Kalli Dircks — Managing Director, Morgan Stanley
- David Lynn — Partner, Goodwin, Public Company Advisory Practice
Due to privacy concerns, this recording is not available.
Learn More about Life Sciences at Goodwin
Life Sciences Practice
Our Life Sciences practice is uniquely positioned to partner with innovators and investors operating in a fast-moving, technology-driven environment. We work with life sciences companies throughout the corporate lifecycle, as well as with investors, banks, and others in the life sciences ecosystem.
Life Sciences Perspectives Blog
Our Life Sciences Perspectives blog is a resource specifically aimed at addressing your most frequent and pressing issues in this dynamic industry. We provide the insights you need most, including developments on private and public company matters, licensing deals and collaborations, patent and IP matters, FDA and healthcare regulatory compliance, and European and Asian developments for life sciences companies.
Related Content & Attendees
- InsightNovember 8, 2024
Life Sciences M&A Trends for 2023 and 2024 (Through End of Q3) in Greater China
- InsightNovember 4, 2024
New Momentum for a Time-Limited Conditional Approval Pathway for Rare Disease Drugs
- InsightNovember 1, 2024
Four Steps to Maximize the Value of AI Innovation in Medtech
- InsightNovember 1, 2024
How the EU AI Act Could Affect Medtech Innovation
- InsightOctober 1, 2024
A Look Ahead in Life Sciences: What We Are Tracking in the Fourth Quarter of 2024 and Beyond
- InsightSeptember 25, 2024
BIOSECURE Act Timeline
- AlertSeptember 12, 2024
Life Sciences Licensing and M&A Update: Catching Up on Recent Decisions Affecting Commercially Reasonable Efforts Definitions and Post-Patent Expiration Royalty Obligations
- InsightSeptember 5, 2024
Antitrust and Competition Life Sciences Quarterly Update Q2 2024
